Abiopharma

New Form 8-K - Wave Life Sciences Ltd. Filed: 2025-09-03 AccNo: 0001193125-25-194511 Size: 181 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits

New Form 8-K - Kiniksa Pharmaceuticals International, plc Filed: 2025-09-03 AccNo: 0001104659-25-086689 Size: 8 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Biogen Highlights Multiple Assets and Indications in Lupus

New Form 8-K - Claritev Corp Filed: 2025-09-03 AccNo: 0001793229-25-000151 Size: 6 MB Item 7.01: Regulation FD Disclosure

New Form 8-K - PALVELLA THERAPEUTICS, INC. Filed: 2025-09-03 AccNo: 0001104659-25-086685 Size: 12 MB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits

Wave Life Sciences Announces Positive Update from Ongoing RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Shock Top and Auntie Anne’s® Make It Official - Beer Kneads Pretzels

Vaxcyte Advances VAX-31 Infant Phase 2 Dose-Finding Study with First Participants Receiving VAX-31 Optimized Dose

Bioventus to Present at the Morgan Stanley 23rd Annual Global Healthcare Conference

TG Therapeutics Announces Completion of Existing Share Repurchase Program and Authorization of New $100 Million Program

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

enGene Achieves Target Enrollment Milestone for LEGEND Trial Pivotal Cohort

Cybin - Cybin to Participate in the Cantor Global Healthcare Conference 2025

BridgeBio to Host Autosomal Dominant Hypocalcemia Type 1 (ADH1) Investor Webinar on Wednesday, September 10th at 8:00 am ET

Cognition Therapeutics Study of Zervimesine (CT1812) in Early Alzheimer’s Disease Reaches 75% Enrollment Target